HPSE and cancer: Heparan sulfate-mimetics [(i.e., Muparfostat, Roneparstat, Necuparanib, PG545 (= Pixatimod)] that inhibit heparanase enzymatic activity are being evaluated in clinical trials for various types of cancer and appear to be well tolerated [16].